Scarica l'app Stockscreener
26.63
1.48%
-0.40
Dopo l'orario di chiusura:
26.63
Oculis Holding Ag Borsa (OCS) Ultime notizie
Risk Check: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Trends & Verified Chart Pattern Signals - baoquankhu1.vn
Aberdeen Group plc Raises Holdings in Oculis Holding AG $OCS - MarketBeat
Oculis Holding (OCS) Is Up 7.9% After EMA PRIME Tag For Optic Neuritis Drug Candidate - simplywall.st
Oculis Holding AG renews $100 million at-the-market offering program - Investing.com
Why (OCS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Stifel raises Oculis stock price target to $50 on pipeline progress - Investing.com
OCS SEC FilingsOculis Holding 10-K, 10-Q, 8-K Forms - Stock Titan
Breakouts Watch: Is Oculis Holding AG Equity Warrant attractive for institutional investorsMarket Risk Analysis & Real-Time Price Movement Reports - baoquankhu1.vn
Can Oculis Holding AG continue delivering strong returnsCEO Change & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Aug Analyst Calls: Should I invest in Oculis Holding AG before earningsQuarterly Profit Review & Reliable Volume Spike Alerts - baoquankhu1.vn
Earnings Recap: How does Oculis Holding AG compare to its peersMarket Sentiment Summary & Target Return Focused Picks - baoquankhu1.vn
Oculis (NASDAQ:OCS) Trading Up 9.2%Time to Buy? - MarketBeat
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis - The Manila Times
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis - GlobeNewswire Inc.
Oculis Holding AG's Privosegtor Receives PRIME Designation from EMA for Treatment of Optic Neuritis, Following FDA Breakthrough Therapy Status - Quiver Quantitative
Oculis drug for sight-threatening optic neuritis wins EMA PRIME - Stock Titan
OCS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Bearish Setup: Whats next for Oculis Holding AG stock2026 Earnings Surprises & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Analyst Upgrade: Should you avoid Oculis Holding AG Equity Warrant stock right now2026 Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First-in-Class Neuroprotective Candidate for Optic Neuritis - Bitget
EPS Watch: Can Oculis Holding AG Equity Warrant be the next market leader2026 Chart Watch & Safe Entry Momentum Stock Tips - baoquankhu1.vn
OCS PE Ratio & Valuation, Is OCS Overvalued - Intellectia AI
Is Positive Privosegtor Phase 2 Optic Neuritis Data Altering The Investment Case For Oculis Holding (OCS)? - Sahm
Short Interest in Oculis Holding AG (NASDAQ:OCS) Declines By 21.5% - MarketBeat
Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities - MarketScreener
Oculis Holding AG (NASDAQ:OCS) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Syquant Capital Sas Invests $3.85 Million in Oculis Holding AG $OCS - MarketBeat
Beyeotech's 2.44M-share stake in Oculis (OCS) equals 4.14% of float - Stock Titan
Oculis (OCS) H.C. Wainwright 26th Annual Global Investment Conference Summary - Quartr
Understanding Momentum Shifts in (OCS) - Stock Traders Daily
Loss Report: Is Oculis Holding AG Equity Warrant a top pick in the sectorTrade Risk Summary & Technical Pattern Recognition Alerts - baoquankhu1.vn
Growth Recap: Is Oculis Holding AG Equity Warrant stock a value trap2026 Earnings Impact & Short-Term Swing Trade Alerts - baoquankhu1.vn
Aug Decliners: Will Oculis Holding AG benefit from green energy policiesWeekly Gains Summary & Technical Entry and Exit Alerts - baoquankhu1.vn
Sentiment Review: Is Oculis Holding AG Equity Warrant benefiting from interest rate changes2026 Winners & Losers & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Revenue Check: Can Oculis Holding AG Equity Warrant stock double in the next year2026 EndofYear Setup & Free Community Consensus Stock Picks - baoquankhu1.vn
Stop Loss: Whats the MACD signal for Oculis Holding AG2026 Stock Rankings & Momentum Based Trading Ideas - baoquankhu1.vn
Oculis Holding AG Presents Promising Phase 2 ACUITY Trial Results for Privosegtor at NANOS 2026 Meeting - quiverquant.com
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting - The Manila Times
Experimental eye drug aims to protect vision in optic neuritis - Stock Titan
Oculis board member buys company stock on March 12 and 13 - Stock Titan
Oculis Holding AG (OCS) reports Q4 loss, tops revenue estimates - MSN
Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 63.9% - MarketBeat
Latest OCS NewsOculis to Participate in Jefferies Healthcar... - Stock Titan
Oculis Holding AG (OCS) Reports Q3 Loss, Beats Revenue Estimates - MSN
Risk Off: Can Oculis Holding AG beat the S P 500Portfolio Risk Report & Weekly Setup with High ROI Potential - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (OCS) Movement - Stock Traders Daily
Aug Opening: What is the implied volatility of Oculis Holding AG Equity WarrantWeekly Investment Report & Safe Capital Investment Plans - baoquankhu1.vn
H.C. Wainwright raises Oculis stock price target to $44 on trial progress - Investing.com Nigeria
Three Oculis executives receive 2026 equity awards, filings show - Stock Titan
Biopharma companies hire new legal executives - BioXconomy
Oculis (NASDAQ:OCS) Sees Large Volume IncreaseHere's What Happened - MarketBeat
OCS: Late-stage pipeline targets DME, dry eye, and neuroprotection, with major data readouts in 2024 - TradingView
[144] Oculis Holding AG SEC Filing - Stock Titan
Oculis (OCS) – Research Analysts’ Recent Ratings Updates - Defense World
Oculis Holding (NasdaqGM:OCS) Valuation Check After Strong Three Year Gains And Recent Share Price Pullback - Yahoo Finance
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):